Jun 28,2022

FDA Approved Device in 2022 | TaiDoc

Based on the customer’s demands, and market trend that Taidoc have submitted cholesterol parameter to FDA and now gratefully to announce that it has passed FDA Class II with 510(k) in June 2022.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 09,2021

Patient Demographics and Clinical Outcomes Among Type 1 Diabetes Patients Using Continuous Glucose Monitors: Data From T1D Exchange Real-World Observational Study

The benefits of Continuous Glucose Monitoring (CGM) on glycemic management have been demonstrated in numerous studies; however, widespread uptake remians limited. The aim of this study was to provide real-world evidence of patient attributes and clinical outcomes associated with CGM use across clinics in the U.S. based T1D Exchange Quality Improvement (T1DX-QI) Collaborative.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

Observed Characteristics Associated With Diabetes Device Use Among Teens With Type 1 Diabetes

Despite advancements in diabetes technologies, disparities remain with respect to diabetes device use in youth with type 1 diabetes (T1D). We compared sociodemographic, diabetes, and psychosocial characteristics associated with device (pump and continuous glucose monitor [CGM]) use in 13- to 17-year-old teens with T1D.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

Analysis of “Multicenter Evaluation Study Comparing a New Factory-Calibrated Real-Time Continuous Glucose Monitoring System to Existing Flash Glucose Monitoring System”

In an article in the Journal of Diabetes Science and Technology, Ji et al. report on the accuracy of a new factory calibrated continuous glucose monitoring system, the AiDEX CGM (Microtech Medical Company, Ltd., Hangzhou, China). This is the first report from a new manufacturer of a highly accurate factory calibrated CGM. The authors report that the accuracy of the AiDEX CGM is comparable to previous results from Abbott Diabetes Care and Dexcom. However, the study protocol was significantly different from previous studies. This study is the first of numerous studies likely from other manufacturers of CGM technology. It raises the question of how to evaluate sensor performance in the coming era of mass adoption of CGM and increased use of automated insulin delivery systems.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

Costs and Outcomes Comparison of Diabetes Technology Usage Among People With Type 1 or 2 Diabetes Using Rapid-Acting Insulin

Does initiation of a continuous glucose monitor (CGM) or insulin pump lower health care utilization and/or costs?

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 25,2021

Use of Continuous Glucose Monitoring in Non-ICU Hospital Settings for People With Diabetes: A Scoping Review of Emerging Benefits and Issues

Evidence indicates that poor glycemic control is associated with increased morbidity and length of stay in hospital. There are a wide range of guidelines published, which seek to ensure safe and effective inpatient glycemic control in the hospital setting. However, the implementation of these protocols is limited in practice. In particular, the feasibility of “flash” and continuous glucose monitoring (CGM) remains untested on general wards.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 29,2021

Evaluation of a Continuous Blood Glucose Monitor: A Novel and Non-Invasive Wearable Using Bioimpedance Technology

Frequent blood glucose level (BGL) monitoring is essential for effective diabetes management. Poor compliance is common due to the painful finger pricking or subcutaneous lancet implantation required from existing technologies. There are currently no commercially available non-invasive devices that can effectively measure BGL. In this real-world study, a prototype non-invasive continuous glucose monitoring system (NI-CGM) developed as a wearable ring was used to collect bioimpedance data. The aim was to develop a mathematical model that could use these bioimpedance data to estimate BGL in real time.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 01,2021

Diabetes technologies for children and adolescents with type 1 diabetes are highly dependent on coverage and reimbursement: results from a worldwide survey

There is a gap in the literature regarding the opinion of multinational healthcare professionals (HCPs) that are directly involved with recommendation of diabetes technologies. In addition, both socioeconomic background of people with diabetes and HCP’s work profile may indirectly impact the willingness to recommend diabetes technologies. Therefore, with this survey, we aimed to comprehensively evaluate the reasons why providers do or do not recommend diabetes devices for children and adolescents with type 1 diabetes.

CLINICAL STUDY

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 10,2021

Signos raises $13M Series A to give you real-time weight-loss advice based on your blood glucose levels

Weight-loss startup Signos is betting that you’re curious enough about the difference between our respective metabolisms to sign up for real-time glucose monitoring and alerts to keep you in shape. It turns out that GV believes that, too, to the tune of leading the company’s $13 million Series A round.

FUNDING SERIES A

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 17,2021

Health2Sync to Launch Asia's First Data Integration of Health Management App and CGM Data

Taiwan-based diabetes management app Health2Sync has launched the latest version of its mobile app for about 200,000 users in Japan that now integrates continuous glucose monitoring data from the Abbott FreeStyle LibreLink mobile app.

PRODUCT

#cgm

#dtx

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM